Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
KDB GLIDE FDA 510(k) Clearance for Expanded Glaucoma Use
New World Medical announced a significant milestone with the receipt of 510(k) indication expansion from the U.S. Food and Drug Administration (FDA) for KDB (Kahook Dual Blade) GLIDE. This clearance allows for the reduction of intraocular pressure (IOP) in adult…
Research Proposes Ranibizumab Over Laser for ROP Treatment
A study led by a University at Buffalo researcher has the potential to revolutionize the treatment of retinopathy of prematurity (ROP), a condition that can lead to blindness in low birthweight premature infants if left untreated. Published in eClinicalMedicine, the…
Oculis Finalizes Phase 2 Trial Enrollment for OCS-05 in AON
Oculis has completed enrollment in its multicenter, randomized, double-blind, placebo-controlled phase 2 ACUITY trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON). Topline results are expected in Q4 2024. The phase 2 ACUITY study…
AsclepiX Completes Enrollment in DISCOVER Trial for Wet AMD
AsclepiX Therapeutics has successfully completed the enrollment for the DISCOVER trial (NCT05859776), which evaluates the safety and tolerability of three different doses of AXT107 (gersizangitide) in patients with wet Age-related Macular Degeneration (AMD). Trial Design and Objectives The trial includes…
Novel Gene Therapy Improves Vision in Children with LCA
In a landmark clinical trial, CRISPR-Cas9 gene editing has proven safe and effective in treating a form of inherited blindness, marking a significant milestone in genetic medicine. The multi-site BRILLIANCE trial, involving the Perelman School of Medicine at the University…
EyePoint’s Duravyu Misses Phase 2 NPDR Trial Goal
EyePoint Pharmaceuticals announced the topline results from its phase 2 PAVIA clinical trial, which evaluated the efficacy of Duravyu (vorolanib intravitreal insert), formerly known as EYP-1901, in treating non-proliferative diabetic retinopathy (NPDR). The trial revealed that Duravyu did not achieve…
Early Patching Shows Promise for Lazy Eye Treatment
A recent study conducted by experts from the University of Leicester sheds light on a potentially more effective treatment approach for children with amblyopia, commonly known as lazy eye. Published in The Lancet, the study challenges the conventional method of…
Emmecell Completes Dosing in Key Corneal Edema Trial
Emmetrope Ophthalmics, a leader in cell-based therapies for severe eye diseases, today announced the completion of the final dose administration in its U.S. clinical trial for EO2002, targeting the treatment of corneal edema. EO2002 Advances Toward Phase 3 This milestone…
Inflammasome Therapeutics Begins GA Clinical Trial
Inflammasome Therapeutics has officially dosed the first patient in a pioneering clinical trial aimed at treating geographic atrophy (GA) resulting from age-related macular degeneration (AMD). This trial, a first-in-class study for a sustained release implant, is sponsored by the University…
How to Slow The Myopia In Children With Contact Lenses
Myopia, or short-sightedness, is one of the most common eye health issues in children and means that they can’t see objects that are far away, causing their vision to blur. Symptoms usually appear between the ages of 8 and 12…